Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 12 de 12
Filtrar
1.
Phytomedicine ; 126: 155442, 2024 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-38394730

RESUMEN

BACKGROUND: The pursuit for safe and efficacious skin-whitening agents has prompted a dedicated exploration of plant-derived compounds. Notably, Tagetes erecta L. flowers have been used as a medicinal extract and possessed in vitro mushroom tyrosinase activity. However, whether polyphenol-enriched fraction extracted from T. erecta L. flowers (TE) regulates melanogenesis within cellular and animal models has not yet been investigated. PURPOSE: This study aimed to investigate the effect of TE as a prospective inhibitor of melanogenesis. METHODS: Through advanced UPLC-QTof/MS analysis, the components of TE were analyzed. Anti-melanogenic effects of TE were evaluated in α-melanocyte-stimulating hormone (α-MSH)-stimulated B16F10 melanoma cells by measuring cell viability assay, extracellular and intracellular melanin biosynthesis, cyclic adenosine monophosphate (cAMP) production, and melanogenesis-related gene and protein expression. Zebrafish larvae were employed for in vivo studies, assessing both heart rate and melanogenesis. Furthermore, molecular docking analyses were employed to predict the interaction between TE components and the melanocortin 1 receptor (MC1R). Direct binding activity of TE components to MC1R was compared with [Nle4, d-Phe7]-MSH (NDP-MSH). RESULTS: TE was found to contain significant phenolic compounds such as patulitrin, quercetagetin, kaempferol, patuletin, and isorhamnetin. This study revealed that TE effectively inhibits melanin biosynthesis in both in vitro and in vivo models. This inhibition was attributed to interference of TE with the cAMP-cAMP response element-binding protein (CREB)-microphthalmia-associated transcription factor (MITF)-tyrosinase pathway, which plays a pivotal role in regulating melanogenesis. Importantly, TE exhibited the remarkable ability to curtail α-MSH-induced melanogenesis in zebrafish larvae without impacting heart rates. Molecular docking analyses predicted that the components of TE possibly interact with the melanocortin 1 receptor, suggesting their role as potential inhibitors of melanin biosynthesis. However, through the direct binding activity compared with NDP-MSH, any TE components did not directly bind to MC1R, suggesting that TE inhibits α-MSH-induced melanogenesis by inhibiting the cAMP-mediated intracellular signaling pathway. The assessment of anti-melanogenic activity, conducted both in vitro and in vivo, revealed that patulitrin and patuletin exhibited significant inhibitory effects on melanin formation, highlighting their potency as major contributors. DISCUSSION: This investigation demonstrated the considerable potential of TE as a natural remedy endowed with remarkable anti-melanogenic properties. The demonstrated capacity of TE to attenuate melanin production by modulating the cAMP-CREB-MITF-tyrosinase pathway underscores its central role in management of disorders associated with excessive pigmentation. Importantly, the implications of these findings extend to the cosmetics industry, where TE emerges as a prospective and valuable ingredient for the formulation of skin-whitening products. The elucidated interactions between TE components and MC1R not only provide insight into a potential mechanism of action but also elevate the significance of this study. In summary, this study not only contributes to our comprehension of pigmentation-related conditions but also firmly establishes TE as a secure and natural strategy for the regulation of melanin production. The innovative aspects of TE propel it into the forefront of potential interventions, marking a noteworthy advancement in the pursuit of effective and safe solutions for pigmentation disorders.


Asunto(s)
Melanoma Experimental , Tagetes , Animales , Melaninas , Monofenol Monooxigenasa/metabolismo , alfa-MSH/farmacología , alfa-MSH/metabolismo , Pez Cebra/metabolismo , Tagetes/metabolismo , Melanogénesis , Polifenoles/farmacología , Receptor de Melanocortina Tipo 1/metabolismo , Simulación del Acoplamiento Molecular , Línea Celular Tumoral , Factor de Transcripción Asociado a Microftalmía/metabolismo , Melanoma Experimental/tratamiento farmacológico , Melanoma Experimental/metabolismo
2.
Clin Exp Allergy ; 46(8): 1066-74, 2016 08.
Artículo en Inglés | MEDLINE | ID: mdl-27196703

RESUMEN

BACKGROUND: α-melanocyte-stimulating hormone (α-MSH) was shown to inhibit allergic airway inflammation and exert suppressive effects on human basophils. OBJECTIVE: This study aims to extend our current knowledge on the melanocortin 1 receptor (MC1R) expression in nasal tissue of patients with allergic rhinitis (AR) and functional effects of α-MSH in human basophils especially from patients with allergic rhinitis. METHODS: MC1R expression before and after nasal allergen provocation was studied in nasal mucosal tissue of AR patients and in a mouse model of allergic airway inflammation using immunofluorescence. In vitro regulation of the MC1R and CD203c surface expression on whole-blood basophils of patients with AR and controls was assessed with flow cytometry. Functional effects of α-MSH on isolated basophils were analysed regarding apoptosis with flow cytometry and chemotaxis using a Boyden chamber assay. RESULTS: We detected an accumulation of MC1R-positive basophils in nasal mucosa tissue of patients with AR 24 h after nasal allergen provocation. Such accumulation was not present in mucosa sections from healthy controls. In mice with allergic airway inflammation, we found a clear accumulation of MC1R-positive basophils in the nasal tissue compared to control mice. MC1R expression was inducible in AR patients and controls by stimulation with anti-IgE. α-MSH inhibited anti-IgE and grass pollen induced upregulation of CD203c, but had no effect on chemotaxis or apoptosis of basophils in vitro. CONCLUSIONS AND CLINICAL RELEVANCE: MC1R-positive basophils accumulate in the nasal mucosa of patients with AR after nasal allergen provocation. Since α-MSH suppresses proinflammatory effector functions in human basophils via the MC1R, it constitutes an interesting novel target for modulating the allergic inflammatory response.


Asunto(s)
Receptor de Melanocortina Tipo 1/metabolismo , Rinitis Alérgica/inmunología , Rinitis Alérgica/metabolismo , Adulto , Alérgenos/inmunología , Animales , Basófilos/inmunología , Basófilos/metabolismo , Biopsia , Quimiotaxis/inmunología , Modelos Animales de Enfermedad , Femenino , Expresión Génica , Humanos , Inmunoglobulina E/inmunología , Masculino , Ratones , Mucosa Nasal/inmunología , Mucosa Nasal/metabolismo , Mucosa Nasal/patología , Pruebas de Provocación Nasal , Hidrolasas Diéster Fosfóricas/metabolismo , Polen/inmunología , Pirofosfatasas/metabolismo , Receptor de Melanocortina Tipo 1/genética , Pruebas de Función Respiratoria , Rinitis Alérgica/diagnóstico , Rinitis Alérgica/genética , Pruebas Cutáneas , Adulto Joven , alfa-MSH/metabolismo
3.
J Med Chem ; 59(7): 3112-28, 2016 Apr 14.
Artículo en Inglés | MEDLINE | ID: mdl-26959173

RESUMEN

Pharmacological probes for the melanocortin receptors have been utilized for studying various disease states including cancer, sexual function disorders, Alzheimer's disease, social disorders, cachexia, and obesity. This study focused on the design and synthesis of bivalent ligands to target melanocortin receptor homodimers. Lead ligands increased binding affinity by 14- to 25-fold and increased cAMP signaling potency by 3- to 5-fold compared to their monovalent counterparts. Unexpectedly, different bivalent ligands showed preferences for particular melanocortin receptor subtypes depending on the linker that connected the binding scaffolds, suggesting structural differences between the various dimer subtypes. Homobivalent compound 12 possessed a functional profile that was unique from its monovalent counterpart providing evidence of the discrete effects of bivalent ligands. Lead compound 7 significantly decreased feeding in mice after intracerebroventricular administration. To the best of our knowledge, this is the first report of a melanocortin bivalent ligand's in vivo physiological effects.


Asunto(s)
Receptores de Melanocortina/agonistas , Receptores de Melanocortina/antagonistas & inhibidores , Animales , Unión Competitiva , Técnicas de Química Sintética , AMP Cíclico/metabolismo , Diseño de Fármacos , Evaluación Preclínica de Medicamentos/métodos , Ingestión de Alimentos/efectos de los fármacos , Femenino , Humanos , Infusiones Intraventriculares , Ligandos , Masculino , Ratones Endogámicos C57BL , Péptidos/química , Péptidos/metabolismo , Péptidos/farmacología , Multimerización de Proteína , Receptor de Melanocortina Tipo 1/metabolismo , Receptor de Melanocortina Tipo 3/metabolismo , Receptor de Melanocortina Tipo 4/metabolismo , Receptores de Melanocortina/metabolismo , Relación Estructura-Actividad
4.
J Immunol ; 194(7): 3381-8, 2015 Apr 01.
Artículo en Inglés | MEDLINE | ID: mdl-25725103

RESUMEN

There is a need for novel approaches to control pathologies with overexuberant inflammatory reactions. Targeting melanocortin (MC) receptors represents a promising therapy for obesity and chronic inflammation, but lack of selectivity and safety concerns limit development. A new way to increase selectivity of biological effects entails the identification of biased agonists. In this study, we characterize the small molecule AP1189 as a biased agonist at receptors MC1 and MC3. Although not provoking canonical cAMP generation, AP1189 addition to MC1 or MC3, but not empty vector, transfected HEK293 cells caused ERK1/2 phosphorylation, a signaling responsible for the proefferocytic effect evoked in mouse primary macrophages. Added to macrophage cultures, AP1189 reduced cytokine release, an effect reliant on both MC1 and MC3 as evident from the use of Mc1r(-/-) and Mc3r(-/-) macrophages. No melanogenesis was induced by AP1189 in B16-F10 melanocytes. In vivo, oral AP1189 elicited anti-inflammatory actions in peritonitis and, upon administration at the peak of inflammation, accelerated the resolution phase by ∼3-fold. Finally, given the clinical efficacy of adrenocorticotropin in joint diseases, AP1189 was tested in experimental inflammatory arthritis, where this biased agonist afforded significant reduction of macroscopic and histological parameters of joint disruption. These proof-of-concept analyses with AP1189, an active oral anti-inflammatory and resolution-promoting compound, indicate that biased agonism at MC receptors is an innovative, viable approach to yield novel anti-inflammatory molecules endowed with a more favorable safety profile.


Asunto(s)
Guanidinas/farmacología , Pirroles/farmacología , Receptores de Melanocortina/agonistas , Receptores de Melanocortina/metabolismo , Animales , Antiinflamatorios/administración & dosificación , Antiinflamatorios/farmacología , Artritis Experimental/tratamiento farmacológico , Artritis Experimental/genética , Artritis Experimental/metabolismo , Artritis Experimental/patología , Calcio/metabolismo , Modelos Animales de Enfermedad , Técnicas de Inactivación de Genes , Guanidinas/administración & dosificación , Células HEK293 , Humanos , Inflamación/tratamiento farmacológico , Inflamación/genética , Inflamación/metabolismo , Inflamación/patología , Macrófagos Peritoneales/efectos de los fármacos , Macrófagos Peritoneales/inmunología , Macrófagos Peritoneales/metabolismo , Masculino , Melaninas/metabolismo , Melanoma Experimental , Ratones , Neutrófilos/inmunología , Neutrófilos/metabolismo , Peritonitis/inducido químicamente , Peritonitis/tratamiento farmacológico , Peritonitis/genética , Peritonitis/metabolismo , Peritonitis/patología , Fagocitosis/inmunología , Pirroles/administración & dosificación , Receptor de Melanocortina Tipo 1/agonistas , Receptor de Melanocortina Tipo 1/genética , Receptor de Melanocortina Tipo 1/metabolismo , Receptor de Melanocortina Tipo 3/agonistas , Receptor de Melanocortina Tipo 3/genética , Receptor de Melanocortina Tipo 3/metabolismo , Receptores de Melanocortina/genética , Transducción de Señal/efectos de los fármacos
5.
PLoS One ; 9(9): e105858, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-25191747

RESUMEN

Proopiomelanocortin-derived peptides exert pleiotropic effects via binding to melanocortin receptors (MCR). MCR-subtypes have been detected in cartilage and bone and mediate an increasing number of effects in diathrodial joints. This study aims to determine the role of MC1-receptors (MC1) in joint physiology and pathogenesis of osteoarthritis (OA) using MC1-signaling deficient mice (Mc1re/e). OA was surgically induced in Mc1re/e and wild-type (WT) mice by transection of the medial meniscotibial ligament. Histomorphometry of Safranin O stained articular cartilage was performed with non-operated controls (11 weeks and 6 months) and 4/8 weeks past surgery. µCT-analysis for assessing epiphyseal bone architecture was performed as a longitudinal study at 4/8 weeks after OA-induction. Collagen II, ICAM-1 and MC1 expression was analysed by immunohistochemistry. Mc1re/e mice display less Safranin O and collagen II stained articular cartilage area compared to WT prior to OA-induction without signs of spontaneous cartilage surface erosion. This MC1-signaling deficiency related cartilage phenotype persisted in 6 month animals. At 4/8 weeks after OA-induction cartilage erosions were increased in Mc1re/e knees paralleled by weaker collagen II staining. Prior to OA-induction, Mc1re/e mice do not differ from WT with respect to bone parameters. During OA, Mc1re/e mice developed more osteophytes and had higher epiphyseal bone density and mass. Trabecular thickness was increased while concomitantly trabecular separation was decreased in Mc1re/e mice. Numbers of ICAM-positive chondrocytes were equal in non-operated 11 weeks Mc1re/e and WT whereas number of positive chondrocytes decreased during OA-progression. Unchallenged Mc1re/e mice display smaller articular cartilage covered area without OA-related surface erosions indicating that MC1-signaling is critical for proper cartilage matrix integrity and formation. When challenged with OA, Mc1re/e mice develop a more severe OA-pathology. Our data suggest that MC1-signaling protects against cartilage degradation and subchondral bone sclerosis in OA indicating a beneficial role of the POMC system in joint pathophysiology.


Asunto(s)
Cartílago Articular/metabolismo , Cartílago Articular/patología , Osteoartritis/etiología , Osteoartritis/patología , Fenotipo , Complicaciones Posoperatorias , Receptor de Melanocortina Tipo 1/metabolismo , Transducción de Señal , Animales , Artritis Experimental , Densidad Ósea , Colágeno Tipo II/metabolismo , Modelos Animales de Enfermedad , Molécula 1 de Adhesión Intercelular/metabolismo , Articulación de la Rodilla/metabolismo , Articulación de la Rodilla/patología , Masculino , Metaloproteinasa 13 de la Matriz/metabolismo , Meniscos Tibiales/patología , Ratones , Osteoartritis/diagnóstico , Osteofito/metabolismo , Factores de Tiempo
6.
Mol Endocrinol ; 28(9): 1423-34, 2014 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-24947673

RESUMEN

In developed nations, the prevalence of obesity and its associated comorbidities continue to prevail despite the availability of numerous treatment strategies. Accumulating evidence suggests that multiple inputs from the periphery and within the brain act in concert to maintain energy metabolism at a constant rate. At the central level, the hypothalamus is the primary component of the nervous system that interprets adiposity or nutrient-related inputs; it delivers hormonal and behavioral responses with the ultimate purpose of regulating energy intake and energy consumption. At the molecular level, enzymes called nutrient energy sensors mediate metabolic responses of those tissues involved in energy balance ( 1 ). Two key energy/nutrient sensors, mammalian target of rapamycin and AMP-activated kinase, are involved in the control of food intake in the hypothalamus as well as in peripheral tissues ( 2 , 3 ). The third more recently discovered nutrient sensor, Sirtuin1 (Sirt1), a nicotinamide adenine dinucleotide-dependent deacetylase, functions to maintain whole-body energy homeostasis. Several studies have highlighted a role for both peripheral and central Sirt1 in regulating body metabolism, but its central role is still heavily debated. Owing to the opaqueness of central Sirt1's role in energy balance are its cell-specific functions. Because of its robust central expression, targeting cell-specific downstream mediators of Sirt1 signaling may help to combat obesity. However, when placed in the context of a physiologically relevant model, there is compelling evidence that central Sirt1 inhibition in itself is sufficient to promote negative energy balance in both the lean and diet-induced obese state.


Asunto(s)
Receptor de Melanocortina Tipo 1/metabolismo , Sirtuina 1/metabolismo , Animales , Peso Corporal , Encéfalo/metabolismo , Metabolismo Energético/fisiología , Proteína Forkhead Box O1 , Factores de Transcripción Forkhead/metabolismo , Humanos , Hipotálamo/metabolismo , Modelos Biológicos , Neuronas/metabolismo , Obesidad/metabolismo , Núcleo Hipotalámico Paraventricular/metabolismo , Transducción de Señal
7.
Clin Exp Immunol ; 177(2): 381-90, 2014 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-24666423

RESUMEN

Alpha-melanocyte stimulating hormone (α-MSH) is a neuropeptide exhibiting anti-inflammatory activity in experimental models of autoimmune diseases. However, no studies thus far have examined the effects of α-MSH on systemic lupus erythematosus (SLE). This study aimed to determine the effects of an α-MSH agonist in induced murine lupus. Here we employed female Balb/cAn mice in which lupus was induced by pristane. Groups of lupus animals were treated daily with the α-MSH analogue [Nle4, DPhe7]-α-MSH (NDP-MSH) (1·25 mg/kg) injected intraperitoneally or saline for 180 days. Normal animals comprised the control group. Arthritis incidence, plasma immunoglobulin (Ig)G isotypes, anti-nuclear antibodies (ANA) and plasma cytokines were evaluated. Renal function was assessed by proteinuria and histopathological lesion. Glomerular levels of IgG, α-smooth muscle actin (α-SMA), inducible nitric oxide synthase (iNOS), C3, CD3, melanocortin receptors (MCR)1, corticotrophin-releasing factor (CRF) and α-MSH was estimated by immunohistochemistry. When compared with normal controls, lupus animals exhibited increased arthritis, IgG levels, ANA, interleukin (IL)-6, IL-10, proteinuria and mesangial cell proliferation together with glomerular expression of α-SMA and iNOS. Glomerular expression of MCR1 was reduced in lupus animals. NDP-MSH treatment reduced arthritis scores by 70% and also diminished IgG1 and IgG2a levels and ANA incidence. In the glomerulus, NDP-MSH treatment reduced cellularity by 50% together with reducing IgG deposits, and expression levels of α-SMA, iNOS and CRF were also all decreased. Taken together, our results suggest for the first time that α-MSH treatment improves several parameters of SLE disease activity in mice, and indicate that this hormone is an interesting potential future treatment option.


Asunto(s)
Lupus Eritematoso Sistémico/metabolismo , alfa-MSH/metabolismo , Animales , Anticuerpos Antinucleares/sangre , Anticuerpos Antinucleares/inmunología , Artritis/tratamiento farmacológico , Artritis/etiología , Artritis/inmunología , Artritis/metabolismo , Hormona Liberadora de Corticotropina/metabolismo , Citocinas/biosíntesis , Modelos Animales de Enfermedad , Femenino , Inmunoglobulina G/sangre , Inmunoglobulina G/inmunología , Glomérulos Renales/efectos de los fármacos , Glomérulos Renales/inmunología , Glomérulos Renales/metabolismo , Glomérulos Renales/patología , Lupus Eritematoso Sistémico/inducido químicamente , Lupus Eritematoso Sistémico/tratamiento farmacológico , Lupus Eritematoso Sistémico/inmunología , Ratones , Óxido Nítrico Sintasa de Tipo II/metabolismo , Receptor de Melanocortina Tipo 1/metabolismo , Terpenos/efectos adversos , alfa-MSH/administración & dosificación
8.
Exp Dermatol ; 22(2): 131-6, 2013 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-23362872

RESUMEN

Melanin performs a crucial role in protecting the skin against harmful ultraviolet light. However, hyperpigmentation may lead to aesthetic problems and disorders such as solar lentigines (SL), melasma, postinflammatory hyperpigmentation and even melanoma. Arthrophytum scoparium grows in the desert in the North African region, and given this type of environment, A. scoparium exhibits adaptations for storing water and produces useful bioactive factors. In this study, the effect of A. scoparium ethanol extract (ASEE) on melanogenesis regulation in B16 murine melanoma cells was investigated. Cells treated with 0.017% (w/v) ASEE showed a significant inhibition of melanin biosynthesis in a time-dependent manner without cytotoxicity. To clarify the mechanism behind the ASEE-treated melanogenesis regulation, the expressions of tyrosinase enzyme and melanogenesis-related genes were determined. Results showed that the expression of tyrosinase enzyme was significantly decreased and Tyr, Trp-1, Mitf and Mc1R mRNA expressions were significantly down-regulated. LC-ESI-TOF-MS analysis of the extract identified the presence of six phenolic compounds: coumaric acid, cinnamic acid, chrysoeriol, cyanidin, catechol and caffeoylquinic acid. The melanogenesis inhibitory effect of ASEE may therefore be attributed to its catechol and tetrahydroisoquinoline derivative content. We report here that ASEE can inhibit melanogenesis in a time-dependent manner by decreasing the tyrosinase protein and Tyr, Trp-1, Mitf and Mc1R mRNA expressions. This is the first report on the antimelanogenesis effect of A. scoparium and on its potential as a whitening agent.


Asunto(s)
Caryophyllaceae/química , Regulación Enzimológica de la Expresión Génica , Regulación Neoplásica de la Expresión Génica , Melanocitos/citología , Monofenol Monooxigenasa/metabolismo , Extractos Vegetales/farmacología , Actinas/metabolismo , Animales , Catecoles/farmacología , Proliferación Celular/efectos de los fármacos , Supervivencia Celular/efectos de los fármacos , Interferón Tipo I/metabolismo , Melaninas/metabolismo , Melanocitos/efectos de los fármacos , Melanoma Experimental , Ratones , Factor de Transcripción Asociado a Microftalmía/metabolismo , Fenoles/farmacología , Proteínas Gestacionales/metabolismo , ARN Mensajero/metabolismo , Receptor de Melanocortina Tipo 1/metabolismo , Tetrahidroisoquinolinas/farmacología
9.
Pigment Cell Melanoma Res ; 25(3): 370-4, 2012 May.
Artículo en Inglés | MEDLINE | ID: mdl-22364200

RESUMEN

Binding of melanocortin peptide agonists to the melanocortin-1 receptor of melanocytes results in eumelanin production, whereas binding of the agouti signalling protein inverse agonist results in pheomelanin synthesis. Recently, a novel melanocortin-1 receptor ligand was reported. A ß-defensin gene mutation was found to be responsible for black coat colour in domestic dogs. Notably, the human equivalent, ß-defensin 3, was found to bind with high affinity to the melanocortin-1 receptor; however, the action of ß-defensin as an agonist or antagonist was unknown. Here, we use in vitro assays to show that ß-defensin 3 is able to act as a weak partial agonist for cAMP signalling in human embryonic kidney (HEK) cells expressing human melanocortin-1 receptor. ß-defensin 3 is also able to activate MAPK signalling in HEK cells stably expressing either wild type or variant melanocortin-1 receptors. We suggest that ß-defensin 3 may be a novel melanocortin-1 receptor agonist involved in regulating melanocyte responses in humans.


Asunto(s)
Receptor de Melanocortina Tipo 1/agonistas , Transducción de Señal/efectos de los fármacos , alfa-MSH/análogos & derivados , beta-Defensinas/farmacología , Proteína de Señalización Agouti/farmacología , Anticarcinógenos/farmacología , AMP Cíclico/metabolismo , Relación Dosis-Respuesta a Droga , Evaluación Preclínica de Medicamentos , Células HEK293 , Humanos , Ligandos , Sistema de Señalización de MAP Quinasas/efectos de los fármacos , Melanocitos/efectos de los fármacos , Melanocitos/metabolismo , Melanocitos/fisiología , Receptor de Melanocortina Tipo 1/metabolismo , Regulación hacia Arriba/efectos de los fármacos , alfa-MSH/farmacología , beta-Defensinas/agonistas , beta-Defensinas/metabolismo
10.
Plant Foods Hum Nutr ; 66(3): 275-84, 2011 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-21656165

RESUMEN

Antioxidant properties of eight Paeonia suffruticosa (Ps) extracts (Ps-1 to Ps-8) were evaluated. The respective half maximally effective concentration (EC(50)) values of Ps-1 ~ 8 were 10.0, 9.8, 63.6, >100, 3.8, 85.1, 6.9, and 0.7 µg/ml for 1,1-diphenyl-2-picrylhydrazyl radical (DPPH·) radical scavenging efficiency and 22.9, 11.4, 53.1, >100, 7.5, 97.6, 43.7, 4.2 µg/ml for 2,2'-azinobis(3-ethylbenzothiazoline-6-sulfonic acid) diammonium salt (ABTS·(+)) radical scavenging capacity. The Ps-8 exhibited high free radical scavenging capacity, ion-chelating ability, reducing power, and inhibition of lipid peroxidation, which may have been attributable to its abundant phenolic and flavonoid content. In Hs68 and B16 cells treated with 100 µg/ml Ps-1, Ps-3, Ps-4 and Ps-6, expressions of toxic activities were lower than those in cells treated with arbutin and ascorbic acid. The antimelanogenesis properties were also tested in B16 cells. Extract Ps-1, and particularly extract Ps-6, considerably inhibited cellular tyrosinase and 3,4-dihydroxyphenylalanine (DOPA) oxidase activity and also reduced melanin content in B16 cells by down-expression of melanocortin-1 receptor (MC1R), microphthalmia-associated transcription factor (MITF), tyrosinase, and tyrosinase-related proteins-1 (TRP-1). The results suggest that P. suffruticosa extracts have antioxidant and antimelanogenesis activities with potential applications in cosmetic materials or food additives.


Asunto(s)
Antioxidantes/farmacología , Flavonoides/farmacología , Melaninas/metabolismo , Paeonia/química , Fenoles/farmacología , Extractos Vegetales/farmacología , Antioxidantes/aislamiento & purificación , Línea Celular , Quelantes/farmacología , Dihidroxifenilalanina/metabolismo , Regulación hacia Abajo , Flavonoides/aislamiento & purificación , Humanos , Interferón Tipo I/metabolismo , Peroxidación de Lípido/efectos de los fármacos , Melanoma Experimental , Factor de Transcripción Asociado a Microftalmía/metabolismo , Monofenol Monooxigenasa/antagonistas & inhibidores , Fenoles/aislamiento & purificación , Fitoterapia , Corteza de la Planta , Extractos Vegetales/aislamiento & purificación , Raíces de Plantas , Proteínas Gestacionales/metabolismo , Receptor de Melanocortina Tipo 1/metabolismo
11.
J Pharm Pharmacol ; 62(9): 1137-45, 2010 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-20796192

RESUMEN

OBJECTIVES: Carotenoids and retinoic acid derivatives are topically applied for sun-protective and whitening purposes. Fucoxanthin is a carotenoid derived from edible sea algae, but its effect on melanogenesis has not been established. Therefore, we examined the effect of fucoxanthin on melanogenesis. METHODS: Inhibitory effects on tyrosinase activity, melanin formation in B16 melanoma and skin pigmentation in UVB-irradiated guinea-pigs were evaluated. To elucidate the action of fucoxanthin on melanogenesis, its effect on skin melanogenic mRNA expression was evaluated in UVB-irradiated mice. Fucoxanthin was given topically or orally to mice once a day and UVB irradiation was applied for 14 days. The effect of fucoxanthin on skin melanogenic mRNA expression was evaluated by real time reverse transcription polymerase chain reaction. KEY FINDINGS: Fucoxanthin inhibited tyrosinase activity, melanogenesis in melanoma and UVB-induced skin pigmentation. Topical application of fucoxanthin (1%) significantly suppressed mRNA expression of cyclooxygenase (COX)-2, endothelin receptor A, p75 neurotrophin receptor (NTR), prostaglandin E receptor 1 (EP1), melanocortin 1 receptor (MC1R) and tyrosinase-related protein 1. The suppression of p75NTR, EP1 and MC1R expressions was observed at 0.01% application. Also, oral application of fucoxanthin (10 mg/kg) significantly suppressed expression of COX-2, p75NTR, EP1 and MC1R. CONCLUSIONS: These results suggest that fucoxanthin exhibits anti-pigmentary activity by topical or oral application in UVB-induced melanogenesis. This effect of fucoxanthin may be due to suppression of prostaglandin (PG) E(2) synthesis and melanogenic stimulant receptors (neurotrophin, PGE(2) and melanocyte stimulating hormone expression).


Asunto(s)
Antineoplásicos Fitogénicos/farmacología , Expresión Génica/efectos de los fármacos , Melaninas/antagonistas & inhibidores , Phaeophyceae/química , Pigmentación de la Piel/efectos de los fármacos , Piel/metabolismo , Xantófilas/farmacología , Animales , Antineoplásicos Fitogénicos/uso terapéutico , Ciclooxigenasa 2/genética , Ciclooxigenasa 2/metabolismo , Cobayas , Masculino , Melaninas/genética , Melanoma/prevención & control , Ratones , Ratones Pelados , Monofenol Monooxigenasa/genética , Monofenol Monooxigenasa/metabolismo , Fitoterapia , Extractos Vegetales/farmacología , Extractos Vegetales/uso terapéutico , ARN Mensajero/metabolismo , Receptor de Melanocortina Tipo 1/genética , Receptor de Melanocortina Tipo 1/metabolismo , Receptor de Factor de Crecimiento Nervioso/genética , Receptor de Factor de Crecimiento Nervioso/metabolismo , Receptores de Endotelina/genética , Receptores de Endotelina/metabolismo , Subtipo EP1 de Receptores de Prostaglandina E/genética , Subtipo EP1 de Receptores de Prostaglandina E/metabolismo , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Piel/efectos de los fármacos , Piel/efectos de la radiación , Pigmentación de la Piel/efectos de la radiación , Rayos Ultravioleta , Xantófilas/uso terapéutico
12.
Eur J Cell Biol ; 86(6): 315-30, 2007 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-17532540

RESUMEN

The murine recessive yellow (Mc1r(e)) is a loss-of-function mutation in the receptor for alpha-melanocyte-stimulating hormone, melanocortin receptor 1 (Mc1r) and produces yellow coats by inducing pheomelanin synthesis in hair follicular melanocytes. However, it is not known whether the Mc1r(e) mutation affects the proliferation and differentiation of melanocytes. In this study, the proliferation and differentiation of recessive yellow epidermal melanocytes cultured in dibutyryl cyclic AMP-supplemented serum-free medium were investigated in detail. The melanocytes produced mainly eumelanin in this culture system. The proliferation of recessive yellow melanocytes was decreased compared with that of wild-type at the e-locus, black melanocytes. The differentiation of melanocytes was also delayed and inhibited in recessive yellow mice. Tyrosinase (TYR) activity and TYR-related protein 1 (TRP1) and TRP2 (dopachrome tautomerase, DCT) expressions were decreased and, in addition, the maturation of stage IV melanosomes was inhibited. Excess l-tyrosine (l-Tyr) added to the culture media rescued the reduced activity of proliferation of melanocytes. l-Tyr also stimulated TYR activity and TRP1 and TRP2 expressions as well as the maturation of stage IV melanosomes and pigmentation. These results suggest that the Mc1r(e) mutation affects the proliferation and differentiation of melanocytes and l-Tyr rescues the reduced proliferative and differentiative activities by stimulating TYR activity and TRP1 and TRP2 expressions as well as melanosome maturation.


Asunto(s)
Diferenciación Celular/efectos de los fármacos , Proliferación Celular/efectos de los fármacos , Melanocitos/metabolismo , Receptor de Melanocortina Tipo 1/metabolismo , Tirosina/farmacología , Animales , Animales Recién Nacidos , Bucladesina/farmacología , Células Cultivadas , Células Epidérmicas , Epidermis/efectos de los fármacos , Epidermis/metabolismo , Femenino , Oxidorreductasas Intramoleculares/metabolismo , Masculino , Melaninas/metabolismo , Melanocitos/citología , Melanocitos/efectos de los fármacos , Melanosomas/ultraestructura , Ratones , Ratones Endogámicos C57BL , Ratones Mutantes , Monofenol Monooxigenasa/metabolismo , Oxidorreductasas/metabolismo , Proteínas Proto-Oncogénicas c-kit/metabolismo , Receptor de Melanocortina Tipo 1/genética
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA